Pharmacokinetic Modeling and Model‐Based Hypothesis Generation for Dose Optimization of Clonidine in Neonates With Neonatal Opioid Withdrawal Syndrome
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3507 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Fei Tang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Clonidine, Neonatal Abstinence Syndrome, Models, Biological, Analgesics, Opioid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NIDA NIH HHS, National Institute on Drug Abuse.
Abstract (Originalsprache)
The No‐POPPY study (NCT03396588), a double‐blind, randomized trial compared morphine with clonidine therapy for neonatal opioid withdrawal syndrome (NOWS) and found that the duration of treatment was similar across groups. This is significant because perinatal use of morphine has the potential for neurodevelopmental consequences. Still, the clonidine group reached symptom stabilization (Finnegan score (FS) < 8) later than the morphine group and had a more significant number of patients who required adjunct therapy. However, the mean FS was consistently lower in the clonidine group after day 6. This prompted us to use pharmacokinetic (PK) and parametric time‐to‐event (TTE) modeling to simulate dosage schedules that may decrease the time to stabilization and reduce the need for adjunct therapy. Population PK (popPK) analysis was conducted, and the final model was a one‐compartment model with first‐order absorption and elimination, incorporating allometric scaling and age effect on apparent clearance (CL/F) and apparent volume (V/F). The population estimates for CL/F and V/F were 13.6 L/h/70 kg and 416 L/70 kg, respectively, similar to the reported values. A Weibull model described the TTE data best, followed by incorporating predicted average concentrations to yield the final Weibull accelerated failure time model. Simulations of dosing strategies showed that increasing both the starting and maximum doses could potentially shorten the time to stabilization, and thus, length of treatment and hospital stay. Given the hypothesis‐generating nature of this analysis, the recommended dosing regimens should be tested prospectively to evaluate their benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genentech, Inc., South San Francisco, California, USA.
- NewGround Pharmaceutical Consulting LLC, Foster City, California, USA.
- St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- University of Kentucky, Lexington, Kentucky, USA.
ORCID-Profile: Fei Tang, Chee M Ng, Jamie Horn, Henrietta S Bada, Markos Leggas
Förderung
- NCATS NIH HHS
- NIDA NIH HHS
- National Institute on Drug Abuse
- National Institutes of Health
Zitieren
APA
Tang, F., Ng, C. M., Horn, J., Bada, H. S., & Leggas, M. (2025). Pharmacokinetic Modeling and Model‐Based Hypothesis Generation for Dose Optimization of Clonidine in Neonates With Neonatal Opioid Withdrawal Syndrome. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3507
Vancouver
Tang F, Ng CM, Horn J, Bada HS, Leggas M. Pharmacokinetic Modeling and Model‐Based Hypothesis Generation for Dose Optimization of Clonidine in Neonates With Neonatal Opioid Withdrawal Syndrome. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3507
BibTeX
@article{Tang2025,
author = {Tang, Fei and Ng, Chee M and Horn, Jamie and Bada, Henrietta S and Leggas, Markos},
title = {Pharmacokinetic Modeling and Model‐Based Hypothesis Generation for Dose Optimization of Clonidine in Neonates With Neonatal Opioid Withdrawal Syndrome},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3507}
}
EUVIMED